Switch to mania after Ayahuasca consumption in a man with bipolar disorder: case report and literature review
DOI:
https://doi.org/10.25118/2763-9037.2018.v8.326Keywords:
Ayahuasca, bipolar disorder, switch to maniaAbstract
Ayahuasca is a tea obtained through the mixture of Brazilian plants. There are several hypotheses that corroborate its antidepressant effects by inhibition of the monoamine oxidase (MAO) enzyme, and there have been reports of switch to mania after its use. This paper describes the case of a 30-year-old man previously diagnosed with bipolar disorder I (BD I), who switched to mania in a mixed episode after consumption of the tea, with remission after abstinence and mood stabilizingtherapy. The literature is still scarce and few case reports have been published so far. In addition to describing the switch to mania, the report highlights the increase of suicidal ideation and behavior associated with the use of the tea in this population. In view of the switch to mania observed in a patient with BD, this report corroborates the hypothesis of antidepressant effects of ayahuasca.
Downloads
References
Dos Santos RG, Bouso JC, Hallak JEC. Ayahuasca: what mental health professionals need to know. Arch Clin Psychiatry. 2017;44:103-9 .
Palhano-Fontes F, Alchieri JC, Maia-de-Oliveira JP, Soares BL, Hallak JEC, Galvão-Coelho N, et al. The therapeuti c potenti als of ayahuasca in the treatment of depression. In: Labate BC, Cavnar C, editors. The therapeuti c use of ayahuasca. Berlim: Springer; 2013. p. 23-39.
Riba J, Valle M, Urbano G, Yriti a M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjecti ve and cardiovascular eff ects, monoamine metabolite excreti on, and pharmacokineti cs. J Pharmacol Exp Ther. 2003;306:73-83.
Godinho AF, Silva MC, Kawashima JD, Horta DF, Anselmo F, De Fraia D. Ayahuasca modifi es amphetamine self ingesti on and modifi es anxiety and locomotor acti vity in adolescent rats. Electronic J Biol. 2017;13:2.
Dos Santos RG. The pharmacology of ayahuasca: a review. Brasilia Med. 2010;47:188-95.
Herraiz T, Gonzalez D. Alcalóides de betacarbolina em Peganum harmala e inibição da monoamina oxidase humana (MAO). Food Chem Toxicol. 2010;48:839-45.
Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JE. Effi cacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systemati c review of systemati c reviews. Expert Rev Clin Pharmacol. 2018;11:889-902.
Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, et al. Ayahuasca: pharmacology, neuroscience and therapeuti c potenti al. Brain Res Bull. 2016;126:89-101.
McKenna DJ. Clinical investi gati ons of the therapeuti c potenti al of ayahuasca: rati onale and regulatory challenges. Pharmacol Ther. 2004;102:111-29.
Malcolm BJ, Lee KC. Ayahuasca: an ancient sacrament for the treatment of contemporary psychiatric illness? Ment Health Clin. 2018;7:39-45.
Tondo L, Vázquez G, Baldessarini RJ. Mania associated with anti depressant treatment: comprehensive meta-analyti c review. Acta Psychiatr Scand. 2010;121:404-14.
Tamada RS, Lafer B; Grupo de Doenças Afeti vas. [Manic episodes during anti depressant treatment in bipolar disorder]. Braz J Psychiatry. 2003;25:171-6.
Dos Santos RG, Osório FL, Crippa JA, Hallak JE. Anti depressive and anxiolyti c eff ects of ayahuasca: a systemati c literature review of animal and human studies. Braz J Psychiatry. 2016;38:65-72.
Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, et al. Anti depressant eff ects of a single dose of Ayahuasca in pati ents with recurrent depression: a SPECT study. J Clin Psicofarmacol. 2016;36:77-81.
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
